
    
      Study A011-13 is Phase 3, randomized, double-blind, placebo-controlled study to evaluate
      sotatercept when added to background PAH therapy in newly diagnosed intermediate- or high
      risk PAH patients.

      Participants enrolled in the study will have a diagnosis within 6 months of study screening
      of symptomatic PAH (WHO Group 1, classified as FC II or III) and presentation of idiopathic
      or heritable PAH, PAH associated with connective tissue diseases (CTD), drug- or toxin-
      induced PAH, post shunt correction PAH, or PAH presenting at least 1 year following the
      correction of congenital heart defects.
    
  